views
![Boost the growth of congenital hyperinsulinism treatment market](https://s3.us-west-2.amazonaws.com/timessquarereporter.com/upload/media/posts/2023-11/20/boost-the-growth-of-congenital-hyperinsulinism-treatment-market_1700478850-b.jpg)
Market Overview:-
Congenital hyperinsulinism is a rare condition characterized by excessive insulin secretion from pancreatic beta cells, leading to episodes of very low blood sugar (hypoglycemia). Common symptoms include excessive sweating, shaking or trembling, seizures, irregular breathing, difficulty feeding, vomiting and difficulty waking. The condition can be treated through diazoxide therapy, octreotide therapy, partial pancreatectomy or near-total pancreatectomy depending on the severity. Recent advances in drug development have expanded treatment options for congenital hyperinsulinism.
Market key trends:-
Increasing research and development activities focused on developing novel drugs for congenital hyperinsulinism treatment is a key trend seen in the market. For instance, Zealand Pharma has developed a long acting GLP-1 analogue called glepaglutide for treatment of congenital hyperinsulinism. The drug has received orphan drug designation from the U.S. FDA. Another key company Rezolute is developing a small molecule called RZ358 that works by selective inhibition of PI3K-ß and PI3K- isoforms to reduce blood insulin levels. If approved, these pipeline drugs will capture a substantial share of the congenital hyperinsulinism treatment market during the forecast period.
Porter’s Analysis:-
- Threat of new entrants: The congenital hyperinsulinism treatment market requires huge R&D investments and regulatory approvals which makes the entry difficult for new players.
- Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment availability remains limited due to the rare nature of the disease.
- Bargaining power of suppliers: Suppliers have significant influence over the prices due to patented drugs and limited availability of generic treatments.
- Threat of new substitutes: There exist few treatment options for congenital hyperinsulinism making the threat of substitutes relatively low.
- Competitive rivalry: The market remains highly competitive with major players focusing on product innovation.
Key Takeaways:-
The global congenital hyperinsulinism treatment market Demand is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing research and development of novel treatment options.
North America region currently dominates the market and is expected to continue its dominance during the forecast period. Presence of major pharmaceutical companies and rising healthcare expenditure contribute to the high market share of North America.
Key players operating in the congenital hyperinsulinism treatment market are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd . Major players are focusing on developing advanced treatment through research collaborations to strengthen their product pipeline.
Read More - https://www.trendingwebwire.com/congenital-hyperinsulinism-treatment-market-share-and-demand-analysis/
![disclaimer](https://www.timessquarereporter.com/disclaimer-timessquarereporter.jpg)
Comments
0 comment